Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 20/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24699322 | 0.90 | TLR8 (0.49) | TLR8TLR7 | |
| SCHEMBL30945301 | 0.90 | TLR8 (0.44) | TLR8TLR7 | |
| SCHEMBL24699665 | 0.89 | TLR8 (0.49) | TLR8TLR7 | |
| SCHEMBL24699259 | 0.89 | TLR8 (0.51) | TLR8TLR7 | |
| SCHEMBL24699321 | 0.89 | TLR8 (0.48) | TLR8TLR7 | |
| SCHEMBL31506965 | 0.88 | TLR8 (0.54) | TLR8TLR7 | |
| SCHEMBL25344140 | 0.88 | TLR8 (0.47) | TLR8TLR7 | |
| SCHEMBL31506973 | 0.87 | TLR8 (0.46) | TLR8TLR7 | |
| SCHEMBL25345701 | 0.87 | TLR8 (0.47) | TLR8TLR7 | |
| SCHEMBL31506969 | 0.87 | TLR8 (0.47) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145575-A1 | MACROMOLECULE-SUPPORTED 8-SULFONYL-BENZAZEPINE COMPOUNDS AND THEIR USES | BOLT BIOTHERAPEUTICS, INC. (US) | 2025-05-08 | — | — | US | disclosed |
| US-20250127914-A1 | ANTIBODY-CONJUGATED 8-SULFONYL-BENZAZEPINE COMPOUNDS AND THEIR USES | BOLT BIOTHERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-20240299569-A1 | 2-AMINO-4-CARBOXAMIDE-BENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240197899-A1 | 2-AMINO-4-CARBOXAMIDE-BENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240091370-A1 | ANTI-HER2 IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2024-03-21 | — | — | US | disclosed |
| EP-4313161-A1 | 2-AMINO-4-CARBOXAMIDE-BENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | Bolt Biotherapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022204536-A1 | 2-AMINO-4-CARBOXAMIDE-BENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022125904-A1 | ANTI-HER2 IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240091370-A1 | ANTI-HER2 IMMUNOCONJUGATES, AND USES THEREOF | ERBB2, LTB4R2, PTGER2 | TLR8 114/4885TLR7 752/4885 |
| US-20250145575-A1 | MACROMOLECULE-SUPPORTED 8-SULFONYL-BENZAZEPINE COMPOUNDS AND THEIR USES | BRD4, MUS81, ABCC8 | TLR8 1341/4885TLR7 3140/4885 |
| US-20240197899-A1 | 2-AMINO-4-CARBOXAMIDE-BENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | AADAC, BRD4, IDO2 | TLR8 3049/4885TLR7 1714/4885 |
| US-20250127914-A1 | ANTIBODY-CONJUGATED 8-SULFONYL-BENZAZEPINE COMPOUNDS AND THEIR USES | BCR, CD22, IGSF11 | TLR8 851/4885TLR7 786/4885 |
| US-20240299569-A1 | 2-AMINO-4-CARBOXAMIDE-BENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | AADAC, BRD4, IDO2 | TLR8 3049/4885TLR7 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.